Basal Insulin Initiation and Maintenance in Adults with Type 2 Diabetes Mellitus in the United States

References

• Blak BT, Smith HT, Hards M, Curtis BH, Ivanyi T. Optimization of insulin therapy in patients with type 2 diabetes mellitus: beyond basal insulin. Diabet Med. 2012;29(7):e13–e20. doi:10.1111/j.1464-5491.2012.03586.x
   PubMedGoogle Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364–1379. doi:10.2337/dc12-0413
   PubMed Web of Science ®Google Scholar
• Sorli C, Heile MK. Identifying and meeting the challenges of insulin therapy in type 2 diabetes. J Multidiscip Healthc. 2014;7:267–282. doi:10.2147/JMDH.S64084
   PubMedGoogle Scholar
• Turner LW, Nartey D, Stafford RS, Singh S, Alexander GC. Ambulatory treatment of type 2 diabetes in the U.S., 1997–2012. Diabetes Care. 2014;37(4):985–992. doi:10.2337/dc13-2097
   PubMedGoogle Scholar
• Ishii H, Iwamoto Y, Tajima N. An exploration of barriers to insulin initiation for physicians in Japan: findings from the Diabetes Attitudes, Wishes And Needs (DAWN) JAPAN study. PLoS One. 2012;7(6):e36361. doi:10.1371/journal.pone.0036361
   PubMed Web of Science ®Google Scholar
• IDF Diabetes Atlas - 7th Edition. International Diabetes Federation. Available from: http://www.diabetesatlas.org/. Accessed May 11, 2016.
   Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140–149. doi:10.2337/dc14-2441
   PubMed Web of Science ®Google Scholar
• Jones S, Benroubi M, Castell C, et al. Characteristics of patients with type 2 diabetes mellitus initiating insulin therapy: baseline data from the INSTIGATE study. Curr Med Res Opin. 2009;25(3):691–700. doi:10.1185/03007990902739669
   PubMed Web of Science ®Google Scholar
• Perez-Nieves M, Kabul S, Desai U, et al. Basal insulin persistence, associated factors, and outcomes after treatment initiation among people with type 2 diabetes mellitus in the US. Curr Med Res Opin. 2016;32(4):669–680. doi:10.1185/03007995.2015.1135789
   PubMed Web of Science ®Google Scholar
• Watson L, Das R, Farquhar R, Langerman H, Barnett AH. Consequences of delaying treatment intensification in type 2 diabetes: evidence from a UK database. Curr Med Res Opin. 2016;32(9):1465–1475. doi:10.1185/03007995.2016.1157462
   PubMed Web of Science ®Google Scholar
• Zografou I, Strachan M, McKnight J. Delay in starting insulin after failure of other treatments in patients with type 2 diabetes mellitus. Hippokratia. 2014;18(4):306–309.
   PubMedGoogle Scholar
• Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011;86(4):304–314. doi:10.4065/mcp.2010.0575
   PubMed Web of Science ®Google Scholar
• Davies MJ, Gagliardino JJ, Gray LJ, Khunti K, Mohan V, Hughes R. Real-world factors affecting adherence to insulin therapy in patients with Type 1 or Type 2 diabetes mellitus: a systematic review. Diabet Med. 2013;30(5):512–524. doi:10.1111/dme.2013.30.issue-5
   PubMedGoogle Scholar
• Polonsky WH, Henry RR. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adherence. 2016;10:1299–1307. doi:10.2147/PPA
   PubMed Web of Science ®Google Scholar
• Rozenfeld Y, Hunt JS, Plauschinat C, Wong KS. Oral antidiabetic medication adherence and glycemic control in managed care. Am J Manag Care. 2008;14(2):71–75.
   PubMed Web of Science ®Google Scholar
• Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006;333(7557):15. doi:10.1136/bmj.38875.675486.55
   PubMed Web of Science ®Google Scholar
• Garcia-Perez LE, Alvarez M, Dilla T, Gil-Guillen V, Orozco-Beltran D. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013;4(2):175–194. doi:10.1007/s13300-013-0034-y
   PubMed Web of Science ®Google Scholar
• Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational global attitudes of patients and physicians in insulin therapy study. Diabet Med. 2012;29(5):682–689. doi:10.1111/j.1464-5491.2012.03605.x
   PubMed Web of Science ®Google Scholar
• Peyrot M, Rubin RR, Khunti K. Addressing barriers to initiation of insulin in patients with type 2 diabetes. Prim Care Diabetes. 2010;4(Suppl 1):S11–S18. doi:10.1016/S1751-9918(10)60004-6
   PubMedGoogle Scholar
• Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care. 2005;28(10):2543–2545. doi:10.2337/diacare.28.10.2543
   PubMed Web of Science ®Google Scholar
• Polonsky WH, Hajos TR, Dain MP, Snoek FJ. Are patients with type 2 diabetes reluctant to start insulin therapy? An examination of the scope and underpinnings of psychological insulin resistance in a large, international population. Curr Med Res Opin. 2011;27(6):1169–1174. doi:10.1185/03007995.2011.573623
   PubMed Web of Science ®Google Scholar
• Oliveria SA, Menditto LA, Ulcickas Yood M, Koo YH, Wells KE, McCarthy BD. Barriers to the initiation of, and persistence with, insulin therapy. Curr Med Res Opin. 2007;23(12):3105–3112. doi:10.1185/030079907X242638
   PubMed Web of Science ®Google Scholar
• Kalirai S, Stephenson J, Perez-Nieves M, et al. Primary care physician perspectives on basal insulin initiation and maintenance in patients with type 2 diabetes mellitus. Prim Care Diabetes. 2017.
   PubMedGoogle Scholar
• Perez-Nieves M, Ivanova JI, Hadjiyianni I, et al. Basal insulin initiation use and experience among people with type 2 diabetes mellitus with different patterns of persistence: results from a multi-national survey. Curr Med Res Opin. 2017;33:1–10.
   Google Scholar
• Peyrot M, Perez-Nieves M, Ivanova J, et al. Correlates of basal insulin persistence among insulin-naive people with type 2 diabetes: results from a multinational survey. Curr Med Res Opin. 2017;33(10):1843–1851. doi:10.1080/03007995.2017.1341868
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes-2017: summary of Revisions. Diabetes Care. 2017;40(Suppl 1):S4–S5. doi:10.2337/dc17-S003
   PubMedGoogle Scholar
• Type 2 diabetes: international survey shows quality of patient-physician conversation at diagnosis linked to better patient outcomes. Available from: https://www.boehringer-ingelheim.com/press-release/type-2-diabetes-international-survey-shows-quality-patient-physician-conversation. Accessed May 11, 2016.
   Google Scholar
• Anderson RM, Funnell MM. Patient empowerment: reflections on the challenge of fostering the adoption of a new paradigm. Patient Educ Couns. 2005;57(2):153–157. doi:10.1016/j.pec.2004.05.008
   PubMed Web of Science ®Google Scholar
• Atreja A, Bellam N, Levy SR. Strategies to enhance patient adherence: making it simple. MedGenMed. 2005;7(1):4.
   PubMedGoogle Scholar
• Carman KL, Dardess P, Maurer M, et al. Patient and family engagement: a framework for understanding the elements and developing interventions and policies. Health Aff (Millwood). 2013;32(2):223–231. doi:10.1377/hlthaff.2012.1133
   PubMed Web of Science ®Google Scholar
• LaSalle JR, Berria R. Insulin therapy in type 2 diabetes mellitus: a practical approach for primary care physicians and other health care professionals. J Am Osteopath Assoc. 2013;113(2):152–162.
   PubMedGoogle Scholar
• Nagelkerk J, Reick K, Meengs L. Perceived barriers and effective strategies to diabetes self-management. J Adv Nurs. 2006;54(2):151–158. doi:10.1111/j.1365-2648.2006.03799.x
   PubMed Web of Science ®Google Scholar
• Rendle KA, May SG, Uy V, Tietbohl CK, Mangione CM, Frosch DL. Persistent barriers and strategic practices: why (asking about) the everyday matters in diabetes care. Diabetes Educ. 2013;39(4):560–567. doi:10.1177/0145721713492218
   PubMedGoogle Scholar
• Schwartz DD, Stewart SD, Aikens JE, Bussell JK, Osborn CY, Safford MM. Seeing the person, not the illness: promoting diabetes medication adherence through patient-centered collaboration. Clin Diabetes. 2017;35(1):35–42. doi:10.2337/cd16-0007
   PubMedGoogle Scholar
• Funnell MM, Brown TL, Childs BP, et al. National standards for diabetes self-management education. Diabetes Care. 2008;31(Suppl 1):S97–S104. doi:10.2337/dc08-S097
   PubMedGoogle Scholar
• Funnell MM, Kruger DF, Spencer M. Self-management support for insulin therapy in type 2 diabetes. Diabetes Educ. 2004;30(2):274–280. doi:10.1177/014572170403000220
   PubMedGoogle Scholar
• Haas L, Maryniuk M, Beck J, et al. National standards for diabetes self-management education and support. Diabetes Care. 2012;35(11):2393–2401. doi:10.2337/dc12-1707
   PubMed Web of Science ®Google Scholar
• Baser O, Tangirala K, Wei W, Xie L. Real-world outcomes of initiating insulin glargine-based treatment versus premixed analog insulins among US patients with type 2 diabetes failing oral antidiabetic drugs. Clinicoecon Outcomes Res. 2013;5:497–505. doi:10.2147/CEOR
   PubMedGoogle Scholar
• Bonafede MM, Kalsekar A, Pawaskar M, et al. A retrospective database analysis of insulin use patterns in insulin-naive patients with type 2 diabetes initiating basal insulin or mixtures. Patient Prefer Adherence. 2010;4:147–156. doi:10.2147/PPA.S10467
   PubMed Web of Science ®Google Scholar
• Cooke CE, Lee HY, Tong YP, Haines ST. Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization. Curr Med Res Opin. 2010;26(1):231–238. doi:10.1185/03007990903421994
   PubMed Web of Science ®Google Scholar
• Davis KL, Tangirala M, Meyers JL, Wei W. Real-world comparative outcomes of US type 2 diabetes patients initiating analog basal insulin therapy. Curr Med Res Opin. 2013;29(9):1083–1091. doi:10.1185/03007995.2013.811403
   PubMed Web of Science ®Google Scholar
• Thayer S, Wei W, Buysman E, et al. The INITIATOR study: pilot data on real-world clinical and economic outcomes in US patients with type 2 diabetes initiating injectable therapy. Adv Ther. 2013;30(12):1128–1140. doi:10.1007/s12325-013-0074-8
   PubMedGoogle Scholar
• Wang L, Wei W, Miao R, Xie L, Baser O. Real-world outcomes of US employees with type 2 diabetes mellitus treated with insulin glargine or neutral protamine Hagedorn insulin: a comparative retrospective database study. BMJ Open. 2013;3(4):e002348. doi:10.1136/bmjopen-2012-002348
   PubMed Web of Science ®Google Scholar
• Wei W, Pan C, Xie L, Baser O. Real-world insulin treatment persistence among patients with type 2 diabetes. Endocr Pract. 2014;20(1):52–61. doi:10.4158/EP13159.OR
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Lage MJ, Perez-Nieves M, et al. Early discontinuation and restart of insulin in the treatment of type 2 diabetes mellitus. Diabetes Ther. 2014;5(1):225–242. doi:10.1007/s13300-014-0065-z
   PubMed Web of Science ®Google Scholar